GU CONNECT has summarised the highlights of the recent ASCO GU 2018 meeting for you.
Renal cell carcinoma (RCC) by Prof. David Pfister, University Hospital of Cologne, Germany
GU CONNECT has summarised the highlights of the recent ASCO GU 2018 meeting for you.
Renal cell carcinoma (RCC) by Prof. David Pfister, University Hospital of Cologne, Germany
After finishing medical school in November 2004 Dr Pfister started his residency in the Department of Urology at the University of Cologne. For his endoscopic training, he switched to the General Hospital in Weiden (Oberpfalz/Bavaria) between August 2006 and March 2007. After returning to Cologne Dr Pfister heightened my oncologic education under Prof. Heidenreich. The oncologic training consisted of two arms: medical and surgical oncology. In 2009 his education was augmented at the University Hospital of Aachen. In 2010 he passed his urologic board exam. Since 2011 Dr Pfister has been working as a staff urologist with main interests in castration-resistant prostate cancer and testicular cancer. In 2011 he passed the Charles Huggins grant, an educational grant at the Center for Prostate Disease Research in Maryland, USA. In 2012 Dr Pfister received an additional qualification in the systemic treatment of solid tumours and since that time he has organised and led the urological clinical trial centre. In 2012 Dr Pfister qualified as a Professor and became an Associate Professor in November 2012 for medical oncologic treatment in urological tumours. At the end of 2015 he became the Commissionary Leader of the Urologic Department of the University of Aachen. Since 2016 Dr Pfister has become the Deputy Director of the Department of Urology, Uro-oncology and Robot-Assisted Surgery, University Hospital of Cologne. Special interest is castration-resistant, radiation-resistant prostate cancer and testicular cancer.
AstraZeneca, Bayer, Merck, MSD, Janssen and Pfizer.
Looking beyond the obvious mutations in non-small-cell lung cancer
Medical experts discuss current and upcoming treatment strategies to use after CDK4/6 inhibitors in patients with ER+/HER2- advanced breast cancer
Make decisions for your patient at two key stages in their journey
Experts discuss new lung cancer data at a meeting hosted by eChinaHealth and COR2ED
Share the survey with patients with lung cancer and their caregivers
Explore pre-analytical phase challenges and biomarker testing in lung cancer. Moderated by the Oncology Brothers.